The Chinese name of Sparsentan is Sparsentan or Sparsentan

About the drugThe Chinese name of Sparsentan, it is often called "Sparsentan" or "Sparsentan". Since this drug has not yet been officially launched in the domestic market, both names are based on transliteration and may be used interchangeably in different literature or reports. But importantly, they all refer to the same drug with an innovative mechanism - Sparsentan. Sparsentan/Sparsentan has demonstrated its unique value in the field of renal disease treatment, especially for the management of primary immunoglobulin A nephropathy in adults. Compared with traditional single-target drugs, its dual inhibition mechanism gives it significant clinical advantages.

Specifically, sparsentan/Sparsentan can simultaneously target angiotensin II and endothelin-1, two bioactive substances that play important roles in cardiovascular and renal physiology. Excessive activation of angiotensin II is associated with various disease states, such as hypertension and proteinuria, while elevation of endothelin-1 is closely linked to fibrosis and inflammatory responses in the kidney. By blocking these two key targets simultaneously, sparsentan/sparsentan not only helps reduce urinary protein excretion, but also effectively improves kidney function and may slow the progression of kidney disease.

Multiple clinical studies have confirmed the safety and efficacy of sparsentan/sparsentan. The drug offers a new treatment option for patients who do not respond well to traditional monotherapy. However, despite its remarkable efficacy, it should be used with caution and close attention should be paid to possible adverse reactions, such as hypotension, rapid deterioration of renal function, or electrolyte imbalance. Therefore, doctors should comprehensively assess the patient's overall health status when prescribing and conduct regular follow-up visits to ensure the safety and effectiveness of treatment.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7354af1-f304-f4d9-e053-2995a90ab219